Related Experiment Videos
Successful thalidomide treatment of severe infantile Behçet disease
1Department of Pediatrics, Rambam Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. r_brik@rambam.health.gov.il
Pediatric Dermatology
|May 19, 2001
Insights
Behçet disease in an infant caused severe mouth ulcers and gastrointestinal issues. Thalidomide treatment effectively resolved these serious mucocutaneous and GI symptoms, indicating its therapeutic potential.
Area of Science:
- Pediatric Rheumatology
- Gastroenterology
- Dermatology
Background:
- Behçet disease is a rare multisystem inflammatory disorder.
- Pediatric onset is uncommon and presents diagnostic challenges.
Observation:
- An 11-month-old infant presented with severe oral ulcers, tongue necrosis, abdominal tenderness, and diarrhea.
- These symptoms were indicative of Behçet disease in a very young child.
Findings:
- The infant's clinical presentation strongly suggested Behçet disease.
- Treatment with thalidomide led to rapid improvement of both mucocutaneous and gastrointestinal symptoms.
Implications:
- This case highlights the importance of considering Behçet disease in infants with unexplained mucocutaneous and GI symptoms.
- Thalidomide demonstrates efficacy in managing severe pediatric Behçet disease, offering a potential treatment avenue.
Abstract:
We describe an 11-month-old child with giant ulcers of the buccal mucosa, necrosis of the tongue, abdominal tenderness, and severe diarrhea due to Behçet disease. Treatment with thalidomide resulted in prompt recovery of the mucocutaneous lesions and gastrointestinal manifestations.